[
  {
    "ts": null,
    "headline": "Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)",
    "summary": "Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I recommend HIMS stock a Hold.",
    "url": "https://finnhub.io/api/news?id=4a0b647f0466c07946d25cc6192f161921418aadee211f0cebc4cdd7f48ef7ff",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739913848,
      "headline": "Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)",
      "id": 132781252,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442209837/image_1442209837.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I recommend HIMS stock a Hold.",
      "url": "https://finnhub.io/api/news?id=4a0b647f0466c07946d25cc6192f161921418aadee211f0cebc4cdd7f48ef7ff"
    }
  },
  {
    "ts": null,
    "headline": "Push UPs [Stocks] Vs Pull DOWNs [Retail Sales]",
    "summary": "This week's review and preview: The S&P 500 and Nasdaq showed bullish behavior, with the Dow Jones leading YTD gains at 4.7%, despite weak retail sales data. Read the full report here.",
    "url": "https://finnhub.io/api/news?id=c31df8fe8b2fca463f42ecc3799b980a278e8518addeb12c05a3ccf4f73c16b1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739897952,
      "headline": "Push UPs [Stocks] Vs Pull DOWNs [Retail Sales]",
      "id": 132780121,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/948513030/image_948513030.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "This week's review and preview: The S&P 500 and Nasdaq showed bullish behavior, with the Dow Jones leading YTD gains at 4.7%, despite weak retail sales data. Read the full report here.",
      "url": "https://finnhub.io/api/news?id=c31df8fe8b2fca463f42ecc3799b980a278e8518addeb12c05a3ccf4f73c16b1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=07fb9754d65138549bbfb576851e3207eb352414444c5a814a8b734a093de46a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739896260,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 132785007,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=07fb9754d65138549bbfb576851e3207eb352414444c5a814a8b734a093de46a"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q4 2024 Update",
    "summary": "Discover the latest strategic moves of Duquesne Family Office's $3.72B portfolio, including new stakes, increased investments, and notable disposals.",
    "url": "https://finnhub.io/api/news?id=8a66f5fb341e73773d5ea7ae74a0c5ed0db7ca45056ecbfc072d6b96625e0ec8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739883867,
      "headline": "Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q4 2024 Update",
      "id": 132778967,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1473159542/image_1473159542.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover the latest strategic moves of Duquesne Family Office's $3.72B portfolio, including new stakes, increased investments, and notable disposals.",
      "url": "https://finnhub.io/api/news?id=8a66f5fb341e73773d5ea7ae74a0c5ed0db7ca45056ecbfc072d6b96625e0ec8"
    }
  },
  {
    "ts": null,
    "headline": "GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'",
    "summary": "GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's rating from Buy to Strong Buy.",
    "url": "https://finnhub.io/api/news?id=79f9d082cf625de8b867702d2868dea83fc96c4cb55e6dce4daad22a8c0a5645",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739845293,
      "headline": "GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'",
      "id": 132765945,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/164210757/image_164210757.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's rating from Buy to Strong Buy.",
      "url": "https://finnhub.io/api/news?id=79f9d082cf625de8b867702d2868dea83fc96c4cb55e6dce4daad22a8c0a5645"
    }
  }
]